Latest from Kromek

Kromek provides the following update on trading for the 12-month period ended 30 April 2025.

Kromek Group plc has further strengthened its senior leadership team with the appointment of Michael Stephenson as Commercial & Strategy Director for its Chemical, Biological, Radiological and Nuclear (CBRN) division to support the company’s ambitious plans for sustainable growth and global expansion.

The prototype of a new machine that can detect tumours in women with dense breast tissue has been developed in Newcastle.

Kromek will be exhibiting at the annual Home Office Security & Policing Global Security Event at the Farnborough International Exhibition and Conference Centre, 11th-13th March 2025 on Stand B105.

First payment under multi-year agreement will enable Kromek to become profitable in the current financial year

Non-exclusive IP licensing and CZT production enablement agreements to generate $37.5m. Kromek expected to become profitable for FY 2025